Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.85
-0.12 (-1.51%)
At close: Feb 11, 2026, 4:00 PM EST
7.85
0.00 (0.00%)
After-hours: Feb 11, 2026, 4:00 PM EST
Gyre Therapeutics Employees
Gyre Therapeutics had 579 employees as of December 31, 2024. The number of employees decreased by 14 or -2.36% compared to the previous year.
Employees
579
Change (1Y)
-14
Growth (1Y)
-2.36%
Revenue / Employee
$185,259
Profits / Employee
$11,487
Market Cap
716.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 579 | -14 | -2.36% |
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| KalVista Pharmaceuticals | 270 |
| Kura Oncology | 192 |
| Alpha Tau Medical | 125 |
| Cullinan Therapeutics | 111 |
| Nektar Therapeutics | 61 |
| AgomAb Therapeutics NV | 58 |
| Fulcrum Therapeutics | 45 |
GYRE News
- 5 weeks ago - Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
- 4 months ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 5 months ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
- 6 months ago - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update - GlobeNewsWire